TNF and Crohn disease: The most commonly used dual biological therapy consisted of an anti-TNF agent and a newer biologic but very limited primary evidence, such as case series [16], suggested that the use of ustekinumab and vedolizumab may be effective for refractory Crohn’s disease with fistula.